Gain Therapeutics Highlights GT-02287 Biomarker Signals, Eyes Phase 2 Start in Q3 at Roth Conference [Yahoo! Finance]
Gain Therapeutics, Inc. (GANX)
Company Research
Source: Yahoo! Finance
and decreases in DOPA decarboxylase, suggesting a GCase stabilizing "gain-of-function" effect and biological proof-of-concept. Gain expects to start Phase 2 in Q3 pending FDA feedback, planning an ~100+ patient all-comers Parkinson's trial with stratification by CSF glucosylsphingosine and MDS-UPDRS Part 2 (supported by Part 3) endpoints aimed at slowing disease progression. Gain's Magellan/AlphaTarget platform pursues allosteric, protein-stabilizing small molecules and the company has backup GCase programs (e.g., GT-04686) to support lifecycle development. Interested in Gain Therapeutics, Inc.? Here are five stocks we like better. Gain Therapeutics (NASDAQ:GANX) is developing oral small-molecule drugs aimed at neurodegenerative diseases, with its lead focus on Parkinson's disease, company CEO Gene Mack said during a fireside chat at a Roth Capital Partners conference. The discussion, hosted by Roth managing director and senior biotech analyst Boobalan Pachaiyappan, centered o
Show less
Read more
Impact Snapshot
Event Time:
GANX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GANX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GANX alerts
High impacting Gain Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
GANX
News
- Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2025 and Provides Corporate Update [Yahoo! Finance]Yahoo! Finance
- Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2025 and Provides Corporate UpdateGlobeNewswire
- Gain Therapeutics to Present at the 38th Annual ROTH Conference [Yahoo! Finance]Yahoo! Finance
- Gain Therapeutics to Present at the 38th Annual ROTH ConferenceGlobeNewswire
- Gain Therapeutics Presents Additional Clinical and Biomarker Data from Phase 1b Clinical Study of GT-02287 and Preclinical Data from Novel Chemical Series at AD/PD 2026 [Yahoo! Finance]Yahoo! Finance
GANX
Sec Filings
- 3/26/26 - Form 4
- 3/26/26 - Form 4
- 3/26/26 - Form 10-K
- GANX's page on the SEC website